Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
22 pending office actions • 11 art units • 20 examiners • 0 of 22 (0%) have an AI response strategy ready
Figene LLC has 23 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 20 distinct examiners and 12 distinct art units. This high number of art units suggests a very broad technological footprint within the pharmaceutical sector, requiring expertise across many different examination groups. The presence of 23 pending office actions across 20 distinct examiners means that most reviewers are only handling a single file.
KELLY, ROBERT M is the busiest examiner, responsible for 3 pending office actions. This diversity in examiners and units necessitates a highly adaptable prosecution strategy to address the specific nuances of 12 different art units. With 23 pending actions, the company must coordinate its responses to ensure that 20 distinct examiners receive a unified message. The involvement of 12 distinct art units is particularly notable, as it indicates the portfolio is subject to a wide range of administrative oversight.
Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (14%) |
| §102 only | 1 (5%) |
| §112 only | 1 (5%) |
| Double-patenting + other | 4 (18%) |
| Multi-statute (no §101) | 13 (59%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KELLY, ROBERT M | 2 | 74.1% | +24.6% |
| LEVIN, JOEL D | 2 | 58.1% | +35.2% |
| CHEN, CATHERYNE | 1 | 37.4% | +18.0% |
| BELYAVSKYI, MICHAIL A | 1 | 64.2% | +27.6% |
| LEONARD, ARTHUR S | 1 | 50.8% | +50.2% |
| FOX, ALLISON M | 1 | 71.2% | +35.7% |
| PALENIK, JEFFREY T | 1 | 53.6% | +27.2% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.7% | +41.4% |
| ZHU, JIANJIAN | 1 | 58.8% | +82.4% |
| HUMPHRIES, NICHOLAS ADAM | 1 | 36.1% | +75.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17310051 | FIBROBLASTS AND MICROVESICLES THEREOF FOR REDUCTION OF TOXICITY ASSOCIATED WITH CANCER IMMUNOTHERAPY | DHAR, MATASHA | 86d overdue |
| 17755834 | FIBROBLAST THERAPY FOR INFLAMMATORY BOWEL DISEASE | MOSS, NATALIE M | 32d overdue |
| 17310007 | FIBROBLAST REGENERATIVE CELLS | TRAN, KHOA NHAT | 25d overdue |
| 17251587 | USE OF FIBROBLASTS AND/OR MODIFIED FIBROBLASTS FOR THREE DIMENSIONAL TISSUE PRINTING | REGLAS, GILLIAN CHELSEA | 27d |
| 18042323 | DENTAL AND PERIODONTAL APPLICATION OF FIBROBLASTS | LEVIN, JOEL D | 34d |
| 17999583 | FIBROBLAST THERAPY FOR PREVENTION AND REVERSION OF ANEURYSMS | FOX, ALLISON M | 42d |
| 17996033 | TREATMENT OF ERECTILE DYSFUNCTION BY FIBROBLAST ADMINISTRATION | ZHU, JIANJIAN | 54d |
| 17997674 | REDUCTION OF CYTOKINE STORM AND PATHOLOGICAL INFLAMMATION INCLUDING CAUSED BY CORONAVIRUS USING SPHAGNUM AND EXTRACTS THEREOF | PALENIK, JEFFREY T | 72d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18486731 | GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | LEONARD, ARTHUR S | 18d overdue |
| 18042323 | DENTAL AND PERIODONTAL APPLICATION OF FIBROBLASTS | LEVIN, JOEL D | 34d |
| 17999583 | FIBROBLAST THERAPY FOR PREVENTION AND REVERSION OF ANEURYSMS | FOX, ALLISON M | 42d |
| 17996033 | TREATMENT OF ERECTILE DYSFUNCTION BY FIBROBLAST ADMINISTRATION | ZHU, JIANJIAN | 54d |
| 17996109 | GENE MODIFIED FIBROBLASTS FOR THERAPEUTIC APPLICATIONS | OGUNBIYI, OLUWATOSIN A | 56d |
| 18615328 | STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES | CHEN, CATHERYNE | 70d |
| 17997674 | REDUCTION OF CYTOKINE STORM AND PATHOLOGICAL INFLAMMATION INCLUDING CAUSED BY CORONAVIRUS USING SPHAGNUM AND EXTRACTS THEREOF | PALENIK, JEFFREY T | 72d |
| 18659833 | FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS | KELLY, ROBERT M | — |
| Art Unit | Apps |
|---|---|
| 1631 | 5 |
| 1633 | 3 |
| 1632 | 3 |
| 1655 | 1 |
| 1615 | 1 |
| 1645 | 1 |
| 1682 | 1 |
| 1644 | 1 |
| 1619 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18659833 | FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS | KELLY, ROBERT M | — | §102§112Other | Non-Final OA | — | Pending | May 09, 2024 |
| 18659876 | FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS | KELLY, ROBERT M | — | §102§112Other | Non-Final OA | — | Pending | May 09, 2024 |
| 18615328 | STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES | CHEN, CATHERYNE | 1655 | DPOther | Non-Final OA | 70d | Pending | Mar 25, 2024 |
| 18603451 | AUGMENTATION OF FIBROBLAST REGENERATIVE ACTIVITY | BELYAVSKYI, MICHAIL A | — | §102DP | Non-Final OA | — | Pending | Mar 13, 2024 |
| 18486731 | GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | LEONARD, ARTHUR S | 1631 | §102§103§112DP | Final Rejection | 18d overdue | Pending | Oct 13, 2023 |
| 18042323 | DENTAL AND PERIODONTAL APPLICATION OF FIBROBLASTS | LEVIN, JOEL D | 1633 | §102§103 | Non-Final OA | 34d | Pending | Feb 21, 2023 |
| 17999583 | FIBROBLAST THERAPY FOR PREVENTION AND REVERSION OF ANEURYSMS | FOX, ALLISON M | 1633 | §102§103Other | Non-Final OA | 42d | Pending | Nov 22, 2022 |
| 17997674 | REDUCTION OF CYTOKINE STORM AND PATHOLOGICAL INFLAMMATION INCLUDING CAUSED BY CORONAVIRUS USING SPHAGNUM AND EXTRACTS THEREOF | PALENIK, JEFFREY T | 1615 | §102§103 | Final Rejection | 72d | Pending | Nov 01, 2022 |
| 17996109 | GENE MODIFIED FIBROBLASTS FOR THERAPEUTIC APPLICATIONS | OGUNBIYI, OLUWATOSIN A | 1645 | §103 | Final Rejection | 56d | Pending | Oct 13, 2022 |
| 17996033 | TREATMENT OF ERECTILE DYSFUNCTION BY FIBROBLAST ADMINISTRATION | ZHU, JIANJIAN | 1631 | §103§112Other | Non-Final OA | 54d | Pending | Oct 12, 2022 |
| 17995609 | IMMUNOTHERAPEUTIC METHODS AND COMPOSITIONS FOR TARGETING CANCER FIBROBLASTS | HUMPHRIES, NICHOLAS ADAM | 1631 | §103DPOther | Final Rejection | — | Pending | Oct 06, 2022 |
| 17905197 | GENERATION OF AUTOIMMUNE INHIBITORY T CELLS BY FIBROBLAST MEDIATED EDUCATION | MIANO, JOSEPH PAUL | 1631 | §103Other | Non-Final OA | 27d | Pending | Aug 29, 2022 |
| 17904180 | TELOMERE LENGTH MODULATION USING FIBROBLASTS | SHEN, WU CHENG WINSTON | 1682 | §102§103§112 | Final Rejection | — | Pending | Aug 12, 2022 |
| 17757383 | SUPPRESSION OF INTERLEUKIN-17 PRODUCTION AND INHIBITION OF TH17 CELL GENERATION BY FIBROBLASTS AND PRODUCTS THEREOF | JOHANSEN, PETER N. | 1644 | §112 | Final Rejection | — | Pending | Jun 15, 2022 |
| 17757314 | AUGMENTATION OF FIBROBLAST MEDIATED REGENERATION OF INTRAVERTEBRAL DISCS | MITCHELL, EDWIN COLEMAN | 1619 | §103§112 | Non-Final OA | — | Pending | Jun 14, 2022 |
| 17755834 | FIBROBLAST THERAPY FOR INFLAMMATORY BOWEL DISEASE | MOSS, NATALIE M | 1653 | §102§103 | Final Rejection | 32d overdue | Pending | May 10, 2022 |
| 17755278 | INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS | CHATTIN, AMY MARIE | 1643 | §102§103§112 | Final Rejection | 72d | Pending | Apr 26, 2022 |
| 17754106 | CANNABIDIOL ADJUVANT THERAPY FOR TREATMENT OF DISC DEGENERATIVE DISEASE | SCHUBERG, LAURA J | 1631 | §103Other | Final Rejection | — | Pending | Mar 24, 2022 |
| 17310051 | FIBROBLASTS AND MICROVESICLES THEREOF FOR REDUCTION OF TOXICITY ASSOCIATED WITH CANCER IMMUNOTHERAPY | DHAR, MATASHA | 1632 | §103§112 | Final Rejection | 86d overdue | Pending | Jul 13, 2021 |
| 17310007 | FIBROBLAST REGENERATIVE CELLS | TRAN, KHOA NHAT | 1632 | §103§112 | Non-Final OA | 25d overdue | Pending | Jul 09, 2021 |
| 17271529 | CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR TREATMENT OF CANCER | LEVIN, JOEL D | 1633 | §102 | Final Rejection | — | Pending | Feb 25, 2021 |
| 17251587 | USE OF FIBROBLASTS AND/OR MODIFIED FIBROBLASTS FOR THREE DIMENSIONAL TISSUE PRINTING | REGLAS, GILLIAN CHELSEA | 1632 | §103§112 | Non-Final OA | 27d | Pending | Dec 11, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial